Search
Paclitaxel Treatment Options in Canada
A collection of 344 research studies where Paclitaxel is the interventional treatment. These studies are located in the Canada . Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
121 - 132 of 344
Show Filters
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Male
Female
Both
Type of Study
Interventional
Observational
Clinical Trial Phase
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
Unknown
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Completed
This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-expressing cancers. This study will also the evaluate the way the body absorbs, distributes, and eliminates ZW25 (pharmacokinetics or PK).
This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-expressing cancers. This study will also the evaluate the way the body absorbs, distributes, and eliminates ZW25 (pharmacokinetics or PK). Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: University of Alabama, Birmingham, Alabama +16 locations
University of Alabama, Birmingham, Alabama
USC/Norris Cancer Center, Los Angeles, California
Hoag Family Cancer Institute, Newport Beach, California
University of Colorado Cancer Center, Aurora, Colorado
Rush University Medical Center, Chicago, Illinois
Sarah Cannon - Tennessee Oncology, Nashville, Tennessee
MD Anderson Cancer Center, Houston, Texas
South Texas Accelerated Research Therapeutics (START), San Antonio, Texas
Northwest Medical Specialties, Tacoma, Washington
University of Ottawa, Ottawa, Ontario
Princess Margaret Cancer Centre, Toronto, Ontario
Jewish General Hospital, Montréal, Quebec
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do
Seoul National University Hospital, Seoul, Not set
Severance Hospital, Seoul, Not set
Asan Medical Center, Seoul, Not set
Samsung Medical Center, Seoul, Not set
Conditions: HER2-expressing Cancers
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
Recruiting
This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients.
This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients. Read Less
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/20/2024
Locations: Toronto General Hospital, Toronto, Ontario
Toronto General Hospital, Toronto, Ontario
Conditions: Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Active Not Recruiting
The primary purpose of this study is to characterize the safety profile of BMS-986408 as monotherapy and in combination with nivolumab or nivolumab and ipilimumab to establish the maximum tolerated dose (MTD). The Recommended Phase 2 Dose (RP2D) that optimizes the pharmacokinetic/pharmacodynamic (PK/PD) relationship of BMS-986408 will also be determined.
The primary purpose of this study is to characterize the safety profile of BMS-986408 as monotherapy and in combination with nivolumab or nivolumab and ipilimumab to establish the maximum tolerated dose (MTD). The Recommended Phase 2 Dose (RP2D) that optimizes the pharmacokinetic/pharmacodynamic (PK/PD) relationship of BMS-986408 will also be determined. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: Local Institution - 0010, Boston, Massachusetts +17 locations
Local Institution - 0010, Boston, Massachusetts
Local Institution - 0001, Hackensack, New Jersey
Local Institution - 0003, Houston, Texas
Local Institution - 0007, Edmonton, Alberta
Local Institution - 0011, Hamilton, Ontario
Local Institution - 0005, Ottawa, Ontario
Local Institution - 0006, Toronto, Ontario
Local Institution - 0015, Bordeaux, Aquitaine
Local Institution - 0014, Villejuif, Paris
Local Institution - 0018, Marseille, Not set
Local Institution - 0019, Toulouse, Not set
Local Institution - 0024, Málaga, Andalucía
Local Institution - 0025, Madrid, Madrid, Comunidad De
Local Institution - 0022, Madrid, Not set
Local Institution - 0023, Madrid, Not set
Local Institution - 0021, st.Gallen, Sankt Gallen
Local Institution - 0012, Basel, Not set
Local Institution - 0020, Geneva, Not set
Conditions: Advanced Solid Tumors
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Active Not Recruiting
The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy.
The primary study hypotheses are that pembrolizumab is superior to the combination of carboplatin and paclitaxel with respect to Progression Free Survival (PFS) per Response Ev... Read More
The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy.
The primary study hypotheses are that pembrolizumab is superior to the combination of carboplatin and paclitaxel with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and Overall Survival (OS). Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: HonorHealth-USOR HonorHealth ( Site 8000), Phoenix, Arizona +194 locations
HonorHealth-USOR HonorHealth ( Site 8000), Phoenix, Arizona
Moores Cancer Center ( Site 0037), La Jolla, California
Kaiser Permanente Riverside Medical Center ( Site 0045), Riverside, California
Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0013), New Haven, Connecticut
Mount Sinai Cancer Center ( Site 0018), Miami Beach, Florida
Sarasota Memorial Hospital ( Site 0005), Sarasota, Florida
Northside Hospital ( Site 0017), Atlanta, Georgia
Southeastern Regional Medical Center ( Site 0046), Newnan, Georgia
Midwestern Regional Medical Center,Inc. DBA CTCA, Chicago ( Site 0003), Zion, Illinois
St. Vincent Hospital and Health Care Center, Inc ( Site 0006), Indianapolis, Indiana
Baptist Health Lexington ( Site 0042), Lexington, Kentucky
Maryland Oncology Hematology, P.A.-USOR Maryland Oncology Hematology, P.A. ( Site 8002), Rockville, Maryland
University of Massachusetts Medical School-Division of Gynecologic Oncology ( Site 0008), Worcester, Massachusetts
Karmanos Cancer Institute ( Site 0029), Detroit, Michigan
St. Dominic's Hospital ( Site 0024), Jackson, Mississippi
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0026), Hackensack, New Jersey
The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0023), New York, New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0016), New York, New York
Icahn School of Medicine at Mount Sinai ( Site 0052), New York, New York
Memorial Sloan Kettering Cancer Center ( Site 0009), New York, New York
FirstHealth Clinical Trials ( Site 0050), Pinehurst, North Carolina
Sanford Medical Center ( Site 0054), Bismarck, North Dakota
Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0055), Fargo, North Dakota
University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0039), Cincinnati, Ohio
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus, Ohio
Providence Portland Medical Center ( Site 0031), Portland, Oregon
Sidney Kimmel Cancer Center - Jefferson Health ( Site 0053), Philadelphia, Pennsylvania
University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0034), Pittsburgh, Pennsylvania
AHN West Penn Hospital ( Site 0011), Pittsburgh, Pennsylvania
Asplundh Cancer Pavilion ( Site 0014), Willow Grove, Pennsylvania
Sanford Cancer Center-Gynecologic Oncology ( Site 0002), Sioux Falls, South Dakota
Texas Oncology - Austin-USOR Texas Oncology - Austin ( Site 8003), Austin, Texas
Texas Oncology - Dallas-USOR Texas Oncology - Dallas (Sammons) ( Site 8005), Dallas, Texas
Texas Oncology - Tyler-USOR Texas Oncology - Northeast Texas ( Site 8004), Tyler, Texas
VCU Health Adult Outpatient Pavillion ( Site 0022), Richmond, Virginia
Northern Cancer Institute ( Site 0206), St Leonards, New South Wales
Westmead Hospital-Department of Gynaecological Oncology ( Site 0201), Westmead, New South Wales
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si, Brisbane, Queensland
Monash Health ( Site 0202), Clayton, Victoria
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0207), Melbourne, Victoria
Epworth Freemasons ( Site 0203), Melbourne, Victoria
St. John of God Subiaco Hospital-Oncology Clinical Trials Unit ( Site 0204), Subiaco, Western Australia
Institut Jules Bordet-Medicine Oncology ( Site 0321), Bruxelles, Bruxelles-Capitale, Region De
Grand Hôpital de Charleroi-Oncology & Hematology ( Site 0323), Charleroi, Hainaut
Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman ( Site 0320), Liège, Liege
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 3005), Natal, Rio Grande Do Norte
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 3001), São Paulo, Sao Paulo
A. C. Camargo Cancer Center-CAPEC ( Site 3003), Sao Paulo, Not set
Cross Cancer Institute ( Site 0513), Edmonton, Alberta
BC Cancer Kelowna ( Site 0517), Kelowna, British Columbia
BC Cancer Vancouver-Clinical Trials Unit ( Site 0518), Vancouver, British Columbia
Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0509), Toronto, Ontario
Princess Margaret Cancer Centre ( Site 0510), Toronto, Ontario
Jewish General Hospital ( Site 0504), Montreal, Quebec
Centre Hospitalier de l'Université de Montréal ( Site 0519), Montréal, Quebec
McGill University Health Centre ( Site 0505), Montréal, Quebec
Saskatoon Cancer Center-Clinical Research Department ( Site 0520), Saskatoon, Saskatchewan
FALP-UIDO ( Site 0602), Santiago, Region M. De Santiago
Pontificia Universidad Catolica de Chile-Centro del Cáncer ( Site 0604), Santiago, Region M. De Santiago
Bradfordhill-Clinical Area ( Site 0603), Santiago, Region M. De Santiago
Anhui Provincial Hospital-Obstetrics and Gynecology ( Site 0730), Hefei, Anhui
Beijing Obstetric and Gynecology Hospital ( Site 0740), Beijing, Beijing
Peking University First Hospital ( Site 0723), Beijing, Beijing
Beijing Cancer hospital ( Site 0715), Beijing, Beijing
Southwest Hospital of Third Military Medical University ( Site 0719), Chongqing, Chongqing
2nd Affiliated Hospital Chongqing Medical Universi ( Site 0745), Chongqing, Chongqing
Fuling Central Hospital ( Site 0733), Fulingqu, Chongqing
Fujian Provincial Cancer Hospital ( Site 0720), Fuzhou, Fujian
SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 0710), Guangzhou, Guangdong
Cancer Hospital of Shantou University Medical College ( Site 0732), Shantou, Guangdong
Affiliated Hospital of Guangdong Medical College ( Site 0731), Zhanjiang, Guangdong
Guangxi Medical University Affiliated Tumor Hospital-Gynecological oncology ( Site 0704), Nanning, Guangxi
Hainan General Hospital ( Site 0703), Haikou, Hainan
Harbin Medical University Cancer Hospital ( Site 0711), Harbin, Heilongjiang
Henan Cancer Hospital ( Site 0713), Zhengzhou, Henan
Wuhan Union Hospital-Medical Oncology ( Site 0716), Wuhan, Hubei
Xiangya Hospital Central South University-Gynecology ( Site 0708), Changsha, Hunan
Hunan Cancer Hospital ( Site 0709), Changsha, Hunan
Jiangsu Province Hospital-Oncology Department ( Site 0707), Nanjing, Jiangsu
The First Affiliated Hospital of Nanchang University ( Site 0729), Nanchang, Jiangxi
The First Hospital of Jilin University ( Site 0705), Changchun, Jilin
Shaanxi Provincial Cancer Hospital ( Site 0714), XI An, Shaanxi
Binzhou Medical University Hospital-Oncology department ( Site 0735), Binzhou, Shandong
Obstetrics & Gynecology Hospital of Fudan University ( Site 0702), Shanghai, Shanghai
Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 0717), Shanghai, Shanghai
West China Second University Hospital Sichuan University ( Site 0701), Chengdu, Sichuan
Tianjin Medical University Cancer Institute and Hospital ( Site 0706), Tianjin, Tianjin
Yunnan Province Cancer Hospital-Gynecology Department ( Site 0721), Kunming, Yunnan
The Affiliated Women's Hospital of Zhejiang University-Obstetrics and Gynecology ( Site 0726), Hangzhou, Zhejiang
Zhejiang Cancer Hospital-Oncology ( Site 0700), Hangzhou, Zhejiang
The First Affiliated Hospital of Wenzhou Medical University-Gynecology ( Site 0725), Wenzhou, Zhejiang
Fakultní nemocnice Brno Bohunice-Gynekologicko-porodnicka klinika ( Site 0404), Brno, Brno-mesto
Fakultni nemocnice Ostrava-Gynekologicko-porodnicka klinika ( Site 0403), Ostrava, Moravskoslezsky Kraj
Nemocnice AGEL Novy Jicin a.s.-Oddeleni radioterapie a onkologie ( Site 0406), Nový Jiín, Novy Jicin
Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0402), Olomouc, Olomoucky Kraj
Vseobecna fakultni nemocnice v Praze-Gynekologicko-porodnicka klinika 1.LF a VFN ( Site 0405), Praha, Praha 2
Fakultni nemocnice Bulovka-Gynekologicko-porodnicka klinika ( Site 0401), Praha, Praha 8
Nemocnice Tomase Bati ve Zline-Onkologické oddělení ( Site 0407), Zlín, Zlinsky Kraj
Fakultni nemocnice Kralovske Vinohrady-Gynekologicko-porodnická klinika ( Site 0408), Praha 10, Not set
Rigshospitalet ( Site 0903), Copenhagen, Hovedstaden
Herlev and Gentofte Hospital ( Site 0902), Copenhagen, Hovedstaden
Aalborg Universitetshospital, Syd ( Site 0905), Aalborg, Nordjylland
Roskilde Sygehus-Oncology department ( Site 0904), Roskilde, Sjaelland
Tampereen yliopistollinen sairaala-Gynecology and Obstetrics ( Site 1001), Tampere, Pirkanmaa
Kuopion Yliopistollinen Sairaala ( Site 1002), Kuopio, Pohjois-Savo
Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 1003), Helsinki, Uusimaa
Universitaetsklinikum Ulm ( Site 1106), Ulm, Baden-Wurttemberg
Universitätsklinikum Bonn-Gynaecological oncology ( Site 1105), Bonn, Nordrhein-Westfalen
Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Frauenheilkunde und Gebur, Dresden, Sachsen
Charité Campus Virchow-Klinikum ( Site 1103), Berlin, Not set
Országos Onkológiai Intézet-Ngyógyászat ( Site 1201), Budapest, Not set
Bon Secours Cork Hospital ( Site 1305), Cork, Not set
St. James's Hospital-Cancer clinical trials office ( Site 1301), Dublin, Not set
Soroka Medical Center ( Site 1403), Be'er Sheva, Not set
Rambam Health Care Campus-Gyneco-oncology unit ( Site 1402), Haifa, Not set
Edith Wolfson Medical Center-Obstetrics & Gynecology ( Site 1405), Holon, Not set
Shaare Zedek Medical Center ( Site 1404), Jerusalem, Not set
Sheba Medical Center ( Site 1401), Ramat Gan, Not set
Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Oncologia Sperimentale Uro-Genitale ( Site 1, Napoli, Campania
IRCCS - AOU di Bologna-SSD Oncologia medica Addarii ( Site 1503), Bologna, Emilia-Romagna
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Oncologia Medica ( Site 1513), Meldola, Emilia-Romagna
Fondazione Policlinico Universitario Agostino Gemelli-Ginecologia Oncologica ( Site 1502), Roma, Lazio
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Chirurgia Ginecologica ( Site 150, Milan, Lombardia
Ospedale Mauriziano-SCDU ONCOLOGIA MEDICA ( Site 1514), Torino, Piemonte
Istituto Nazionale Tumori Regina Elena-Oncologia Medica 1 ( Site 1504), Rome, Roma
Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 1509), Firenze, Toscana
AULSS8 Berica-Ospedale S.Bortolo-ONCOLOGIA CLINICA ( Site 1510), Vicenza, Veneto
Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 1506), Milano, Not set
National Cancer Center Hospital East ( Site 1604), Kashiwa, Chiba
National Hospital Organization Shikoku Cancer Center ( Site 1611), Matsuyama, Ehime
Ehime University Hospital ( Site 1614), Toon, Ehime
Kurume University Hospital ( Site 1612), Kurume, Fukuoka
Gunma Prefectural Cancer Center-Gynecology ( Site 1603), Ota, Gunma
Hokkaido University Hospital ( Site 1601), Sapporo, Hokkaido
Tsukuba University Hospital ( Site 1618), Tsukuba, Ibaraki
Iwate Medical University Hospital ( Site 1602), Shiwa-gun Yahaba-cho, Iwate
Niigata University Medical & Dental Hospital ( Site 1613), Chuo-ku, Niigata, Niigata
Saitama Medical University International Medical Center ( Site 1605), Hidaka-shi, Saitama
Shizuoka Cancer Center ( Site 1609), Nagaizumi-cho,Sunto-gun, Shizuoka
National Cancer Center Hospital ( Site 1607), Chuo-ku, Tokyo
Japanese Foundation for Cancer Research ( Site 1616), Koto, Tokyo
The Jikei University Hospital ( Site 1615), Minato-ku, Tokyo
Keio university hospital ( Site 1606), Shinjyuku-ku, Tokyo
National Hospital Organization Kyushu Cancer Center ( Site 1608), Fukuoka, Not set
Osaka International Cancer Institute ( Site 1617), Osaka, Not set
Seoul National University Hospital ( Site 2302), Seoul, Not set
Severance Hospital, Yonsei University Health System-Gynecologic cancer center ( Site 2301), Seoul, Not set
Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology ( Site 2303), Seoul, Not set
Gangnam Severance Hospital ( Site 2304), Seoul, Not set
Radboudumc-Medical Oncology ( Site 1703), Nijmegen, Gelderland
Maastricht UMC+ ( Site 1709), Maastricht, Limburg
Catharina Ziekenhuis-Oncology ( Site 1704), Eindhoven, Noord-Brabant
Amsterdam UMC, locatie AMC ( Site 1706), Amsterdam, Noord-Holland
Leids Universitair Medisch Centrum-Medical Oncology ( Site 1702), Leiden, Zuid-Holland
Erasmus Medisch Centrum-Medical Oncology ( Site 1701), Rotterdam, Zuid-Holland
University Medical Center Groningen ( Site 1707), Groningen, Not set
Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 1705), Utrecht, Not set
Auckland City Hospital-Cancer & Blood Research ( Site 1801), Auckland, Not set
Oslo universitetssykehus, Radiumhospitalet ( Site 1901), Oslo, Not set
Centrum Onkologii Ziemi Lubelskiej ( Site 2006), Lublin, Lubelskie
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2007), Siedlce, Mazowieckie
Szpital Kliniczny im. Księżnej Anny Mazowieckiej ( Site 2009), Warsaw, Mazowieckie
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Ginekologii Onkologicznej ( Sit, Warszawa, Mazowieckie
Bialostockie Centrum Onkologii-Oddzial Onkologii Ginekologicznej ( Site 2003), Bialystok, Podlaskie
Narodowy Instytut Onkologii - Oddzial w Gliwicach-III Klinika Radioterapii i Chemioterapii ( Site 20, Gliwice, Slaskie
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 2010), Kielce, Swietokrzyskie
Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Me-Oddzial Ginekologii Onkologicznej ( Sit, Poznan, Wielkopolskie
Moscow City Oncology Hospital #62 ( Site 2204), Krasnogorsk, Moskovskaya Oblast
Yaroslavl Regional Cancer Hospital-Oncology ( Site 2202), Yaroslavl, Yaroslavskaya Oblast
Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 2406), Hospitalet, Barcelona
CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 2405), A Coruña, La Coruna
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 2402), Madrid, Madrid, Comunidad De
COMPLEJO HOSPITALARIO DE NAVARRA ( Site 2407), Pamplona, Navarra
Fundación Instituto Valenciano de Oncología-Oncologico ( Site 2404), Valencia, Valenciana, Comunitat
Hospital Universitari Vall d'Hebron ( Site 2403), Barcelona, Not set
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 2401), Sevilla, Not set
Skånes Universitetssjukhus Lund-Department of Hematology ( Site 2504), Lund, Skane Lan
Karolinska Universitetssjukhuset Solna ( Site 2502), Solna, Stockholms Lan
Norrlands universitetssjukhus-Cancercentrum ( Site 2503), Umeå, Vasterbottens Lan
Taichung Veterans General Hospital ( Site 2602), Taichung, Not set
NATIONAL CHENG-KUNG UNI. HOSP. ( Site 2604), Tainan, Not set
National Taiwan University Hospital ( Site 2603), Taipei, Not set
Mackay Memorial Hospital ( Site 2601), Taipei, Not set
Taipei Veterans General Hospital ( Site 2605), Taipei, Not set
Istanbul Universitesi Cerrahpasa ( Site 2702), Fatih, Istanbul
Hacettepe Universite Hastaneleri-oncology hospital ( Site 2704), Ankara, Not set
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 2706), Ankara, Not set
Akdeniz Universitesi Hastanesi ( Site 2701), Antalya, Not set
Istanbul University Capa Campus-department of obstetrics and gynaecology ( Site 2705), Istanbul, Not set
T.C. Saglik Bakanligi Turkiye Kamu Hastaneleri Kurumu - Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma, Istanbul, Not set
St Bartholomew's Hospital ( Site 2804), London, England
The Christie ( Site 2807), Manchester, England
The Beatson West of Scotland Cancer Centre ( Site 2805), Glasgow, Glasgow City
ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 2806), London, London, City Of
Hammersmith Hospital-Medical Oncology ( Site 2808), London, London, City Of
Conditions: Endometrial Neoplasms
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Completed
This is a multi-center, randomized, open-label, phase 1/2 study of continuous weekly paclitaxel and escalating doses of intermittent or continuous OSI-906 in patients with recurrent/relapsed ovarian and other solid tumors.
This is a multi-center, randomized, open-label, phase 1/2 study of continuous weekly paclitaxel and escalating doses of intermittent or continuous OSI-906 in patients with recurrent/relapsed ovarian and other solid tumors. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: Mayo Clinic, Scottsdale, Arizona +45 locations
Mayo Clinic, Scottsdale, Arizona
Department of Obstetrics and Gynecology, University of California, Irvine, Orange, California
Horizon Oncology Center, Lafayette, Indiana
Ochsner Clinic Foundation, New Orleans, Louisiana
Morristown Memorial Hospital, Morristown, New Jersey
Blumenthal Cancer Center - Main, Charlotte, North Carolina
Duke University Medical Center, Durham, North Carolina
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
WestMead Hospital, WestMead, New South Wales
Mater Adult Hospital, South Brisbane, Queensland
Royal Adelaide Hospital, North Terrace, South Australia
Launceston General Hospital, Launceston, Tasmania
Frankston Hospital, Frankston, Victoria
Border Medical Oncology, Wodonga, Victoria
St. John of God Hospital, Bunbury, Bunbury, Western Australia
Sir Charles Gairdner Hospital, Perth, Western Australia
St. John of Gog Hospital, Subiaco, Subiaco, Western Australia
Juravinski Cancer Center, Hamilton, Ontario
Princess Margaret Hospital, Toronto, Ontario
McGill University, Montreal, Quebec
University Hospital Hradec Kralove, Kralove, Not set
University Hospital Ostrava, Ostrava- Poruba, Not set
General University Hospital, Department of Obstetrics and Gynecology, Prague, Not set
Universitaria di Bologna Policlinico, Bologna, Not set
Ospedale di Carpi, AUSL di Modena, Carpi, Not set
Instituto Europeo di Oncologia, Milan, Not set
Oncology IDI- IRCSS, Roma, Not set
III Oddzial Onkologii Ginekologicznej, Lublin, Not set
Oddzial Radioterapii, Poznan, Not set
Klinika Onkologii AM w Poznaniu, Poznan, Not set
Institutul Oncologic Prof. Dr. Ion. Chiricuta Sectia de Oncologie Medicala, Cluj Napoca, Not set
Institutul Oncologic Prof. Dr. Ion. Chiricuta Sectia Radiologie, Cluj Napoca, Not set
Oncology Medical Centre SCM, Iasi, Not set
Clinical Caunty Hospital Mures, Mures, Not set
Central Clinical Hospital, Moscow, Not set
Moscow City Oncology Hospital, Moscow, Not set
State Institution Medical Radiology Scientific Center, Obninsk, Not set
Sity Clinical Oncology, St. Petersburg, Not set
Ospedale San Giovanni, Bellinzona, Not set
Drug Development Unit Royal Mardsen NHS Foundation Trust, Sutton, Surrey
Royal Marsden Hospital, London, Not set
University College Hospital, London, Not set
The Christie NHS Foundation Trust, Manchester, Not set
Mount Vernon Cancer Center, Northwood, Not set
Churchill Hospital, Oxford, Not set
Christie NHS Foundation Trust, Withington, Not set
Conditions: Ovarian Cancer, Solid Tumors
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Completed
The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.
The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2024
Locations: Southern Cancer Center, Inc., Mobile, Alabama +289 locations
Southern Cancer Center, Inc., Mobile, Alabama
Local Institution - 0017, San Francisco, California
Local Institution - 0021, New Haven, Connecticut
Local Institution - 0001, Atlanta, Georgia
Local Institution - 0013, Marietta, Georgia
Local Institution - 0004, Lexington, Kentucky
Local Institution - 0115, Saint Louis, Missouri
Local Institution - 0005, Buffalo, New York
Local Institution - 0019, New York, New York
Local Institution - 0014, Cleveland, Ohio
Local Institution - 0009, Columbus, Ohio
Local Institution - 0007, Allentown, Pennsylvania
Local Institution - 0075, Langhorne, Pennsylvania
Local Institution - 0299, Philadelphia, Pennsylvania
Local Institution - 0012, Philadelphia, Pennsylvania
Local Institution - 0015, Sayre, Pennsylvania
Local Institution - 0008, Charleston, South Carolina
Local Institution - 0080, Greenville, South Carolina
Local Institution - 0010, Greenville, South Carolina
Local Institution - 0020, Nashville, Tennessee
Local Institution - 0306, Dallas, Texas
Local Institution - 0003, Dallas, Texas
Local Institution - 0102, Houston, Texas
Local Institution - 0011, Salt Lake City, Utah
Local Institution - 0074, Kennewick, Washington
Local Institution - 0170, Berazategui, Buenos Aires
Local Institution - 0171, Capital Federal, Buenos Aires
Local Institution - 0172, Ciudad Autonoma De Buenos Aire, Buenos Aires
Local Institution - 0176, Ciudad de Buenos Aires, Buenos Aires
Local Institution - 0296, Mar Del Plata, Buenos Aires
Local Institution - 0177, Viedma, RIO Negro
Local Institution - 0130, San Miguel de Tucuman, Tucuman
Local Institution - 0268, Cordoba, Not set
Local Institution - 0272, Córdoba, Not set
Local Institution - 0297, Córdoba, Not set
Local Institution - 0182, Garran, Australian Capital Territory
Local Institution - 0301, Blacktown, New South Wales
Local Institution - 0300, Gosford, New South Wales
Local Institution - 0045, Brisbane, Queensland
Local Institution - 0046, Elizabeth Vale, South Australia
Local Institution - 0043, Clayton, Victoria
Local Institution - 0042, Fitzroy, Victoria
Local Institution - 0180, Perth, Western Australia
Local Institution - 0040, Murdoch, Not set
Local Institution - 0183, North Tamworth, Not set
Local Institution - 0241, Graz, Not set
Local Institution - 0240, Vienna, Not set
Local Institution - 0239, Wels, Not set
Local Institution - 0121, Roeselare, West-Vlaanderen
Local Institution - 0030, Edegem, Not set
Local Institution - 0031, Gent, Not set
Local Institution - 0034, Gilly, Not set
Local Institution - 0117, Hasselt, Not set
Local Institution - 0033, Sint Niklaas, Not set
Local Institution - 0125, Salvador, Bahia
Local Institution - 0124, Ijui, RIO Grande DO SUL
Local Institution - 0123, Porto Alegre, Rio Grande Do Sul
Local Institution - 0127, Barretos, Sao Paulo
Local Institution - 0129, Rio De Janeiro, Not set
Local Institution - 0144, Sao Paulo, Not set
Local Institution - 0126, Sao Paulo, Not set
Local Institution - 0128, Sao Paulo, Not set
Local Institution - 0103, Edmonton, Alberta
Local Institution - 0290, St. John's, Newfoundland and Labrador
Local Institution - 0104, London, Ontario
Local Institution - 0122, Montreal, Quebec
Local Institution - 0106, Quebec City, Quebec
Local Institution - 0107, Rimouski, Quebec
Local Institution - 0291, Sherbrooke, Quebec
Local Institution - 0292, Trois-Rivieres, Quebec
Local Institution - 0302, Quebec, Not set
Local Institution - 0173, Santiago, Metropolitana
Local Institution - 0131, Santiago, Región Metropolitana De Santiago
Local Institution - 0174, Vina Del Mar, Valparaiso
Local Institution - 0380, Hefei, Anhui
Local Institution - 0313, Beijing, Beijing
Local Institution - 0315, Beijing, Beijing
Local Institution - 0316, Beijing, Beijing
Local Institution - 0314, Beijing, Beijing
Local Institution - 0365, Chongqing, Chongqing
Local Institution - 0364, Chongqing, Chongqing
Local Institution - 0378, Chongqing, Chongqing
Local Institution - 0322, Guangzhou, Guangdong
Local Institution - 0372, Guangzhou, Guangdong
Local Institution - 0319, Guanzhou, Guangdong
Local Institution - 0323, Haikou, Hainan
Local Institution - 0325, Haerbin, Heilongjiang
Local Institution - 0324, Zhengzhou, Henan
Local Institution - 0379, Zhengzhou, Henan
Local Institution - 0375, Wuhan, Hubei
Local Institution - 0362, Changsha, Hunan
Local Institution - 0347, Nanchang, Jiangxi
Local Institution - 0329, Changchun, Jilin
Local Institution - 0361, Changchun, Jilin
Local Institution - 0359, Shenyang, Liaoning
Local Institution - 0371, Xi'an, Shaanxi
Local Institution - 0333, Xi'an, Shan3xi
Local Institution - 0360, Qingdao, Shandong
Local Institution - 0334, Shanghai, Shanghai
Local Institution - 0376, Chengdu, Sichuan
Local Institution - 0373, Tianjin, Tianjin
Local Institution - 0340, Urumqi, Xinjiang
Local Institution - 0343, Hangzhou, Zhejiang
Local Institution - 0370, Hangzhou, Zhejiang
Local Institution - 0342, Hangzhou, Zhejiang
Local Institution - 0328, Changsha, Not set
Local Institution - 0341, Hangzhou, Not set
Local Institution - 0345, Kunming, Not set
Local Institution - 0336, Shanghai, Not set
Local Institution - 0337, Shanghai, Not set
Local Institution - 0374, Shantou, Not set
Local Institution - 0273, Pereira, Risaralda
Local Institution - 0237, Bogota, Not set
Local Institution - 0238, Bogota, Not set
Local Institution - 0282, Medellin, Not set
Local Institution - 0112, Hradec Kralove, Not set
Local Institution - 0113, Olomouc, Not set
Local Institution - 0111, Praha 4, Not set
Local Institution - 0232, Pribram, Not set
Local Institution - 0270, Oulu, Not set
Local Institution - 0271, Turku, Not set
Local Institution - 0222, Bron, Rhône
Local Institution - 0216, ANGERS Cedex 2, Not set
Local Institution - 0229, Besançon Cedex, Not set
Local Institution - 0283, Caen, Not set
Local Institution - 0218, Creteil, Not set
Local Institution - 0228, Limoges, Not set
Local Institution - 0215, Marseille Cedex 20, Not set
Local Institution - 0230, Paris, Not set
Local Institution - 0227, Pessac, Not set
Local Institution - 0223, Rennes, Not set
Local Institution - 0225, Rouen, Not set
Local Institution - 0221, Saint Priest En Jarez, Not set
Local Institution - 0217, Saint-herblain Cedex, Not set
Local Institution - 0224, Strasbourg, Not set
Local Institution - 0226, Toulon, Not set
Local Institution - 0231, Magdeburg, Sachsen-Anhalt
Local Institution - 0213, Bad Berka, Not set
Local Institution - 0208, Berlin, Not set
Local Institution - 0205, Essen, Not set
Local Institution - 0210, Frankfurt, Not set
Local Institution - 0211, Gera, Not set
Local Institution - 0203, Grosshansdorf, Not set
Local Institution - 0209, Halle, Not set
Local Institution - 0202, Heidelberg, Not set
Local Institution - 0214, Hemer, Not set
Local Institution - 0206, Immenstadt, Not set
Local Institution - 0204, Muenchen, Not set
Local Institution - 0201, Stuttgart, Not set
Local Institution - 0212, Wiesbaden, Not set
Local Institution - 0094, Athens, Attikí
Local Institution - 0095, Heraklion, Not set
Local Institution - 0190, Neo Faliro, Not set
Local Institution - 0101, Thessaloniki, Not set
Local Institution - 0025, Budapest, Not set
Local Institution - 0024, Budapest, Not set
Local Institution - 0026, Matrahaza, Not set
Local Institution - 0054, Dublin 8, Dublin
Local Institution - 0053, Beaumont, Not set
Local Institution - 0055, Galway, Not set
Local Institution - 0100, Limerick, Not set
Local Institution - 0187, Jerusalem, Not set
Local Institution - 0186, Kfar-saba, Not set
Local Institution - 0185, Petach Tikva, Not set
Local Institution - 0184, Tel-hashomer, Not set
Local Institution - 0188, Zerifin, Not set
Local Institution - 0083, Milan, Lombardia
Azienda Ospedaliera Moscati, Avellino, Not set
Local Institution - 0179, Bergamo, Not set
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, Not set
Local Institution - 0084, Livorno, Not set
Policlinico G. Martino, Messina, Not set
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Not set
Istituto Nazionale Tumori Fondazione Pascale, Napoli, Not set
Local Institution - 0087, Perugia, Not set
Ospedale Santa Maria delle Croci, Ravenna, Not set
Ifo-Istituto Regina Elena, Roma, Not set
Local Institution - 0089, Roma, Not set
Local Institution - 0085, Terni, Not set
Local Institution - 0153, Nagoya-shi, Aichi
Local Institution - 0152, Nagoya, Aichi
Local Institution - 0148, Kashiwa-shi, Chiba
Local Institution - 0159, Matsuyama, Ehime
Local Institution - 0160, Fukuoka-shi, Fukuoka
Local Institution - 0259, Kurume-shi, Fukuoka
Local Institution - 0255, Ota-shi, Gunma
Local Institution - 0258, Hiroshima-shi, Hiroshima
Local Institution - 0163, Sapporo-shi, Hokkaido
Local Institution - 0253, Sapporo-shi, Hokkaido
Local Institution - 0252, Akashi-shi, Hyogo
Local Institution - 0156, Kobe-shi, Hyogo
Local Institution - 0146, Kanazawa-shi, Ishikawa
Local Institution - 0161, Yokohama-shi, Kanagawa
Local Institution - 0150, Yokohama-Shi, Kanagawa
Local Institution - 0275, Natori-shi, Miyagi
Local Institution - 0254, Sendai-shi, Miyagi
Local Institution - 0145, Sendai-shi, Miyagi
Local Institution - 0164, Niigata-shi, Niigata
Local Institution - 0158, Kurashiki-shi, Okayama
Local Institution - 0155, Hirakata-shi, Osaka
Local Institution - 0154, Osaka-shi, Osaka
Local Institution - 0251, Osakasayama-shi, Osaka
Local Institution - 0257, Takatsuki-shi, Osaka
Local Institution - 0353, Hidaka-shi, Saitama
Local Institution - 0256, Kitaadachi-gun, Saitama
Local Institution - 0151, Sunto-gun, Shizuoka
Local Institution - 0147, Chuo-ku, Tokyo
Local Institution - 0149, Koto-ku, Tokyo
Local Institution - 0278, Shinjuku-ku, Tokyo
Local Institution - 0157, Wakayama-shi, Wakayama
Local Institution - 0354, Ube-shi, Yamaguchi
Local Institution - 0260, Chiba, Not set
Local Institution - 0165, Okayama, Not set
Local Institution - 0162, Tokyo, Not set
Local Institution - 0136, Seongnam-si, Kyǒnggi-do
Local Institution - 0249, Cheongju-si, Not set
Local Institution - 0133, Gangnam-gu, Not set
Local Institution - 0132, Seoul, Not set
Local Institution - 0135, Seoul, Not set
Local Institution - 0287, Beirut, Not set
Local Institution - 0286, Beirut, Not set
Local Institution - 0196, Df, Distrito Federal
Local Institution - 0193, Mexico, Distrito Federal
Local Institution - 0198, Cuautitlan, Estado DE Mexico
Local Institution - 0197, Guadalajara, Jalisco
Local Institution - 0191, Zapopan, Jalisco
Local Institution - 0267, Morelia, Michoacan
Local Institution - 0277, Monterrey, Nuevo Leon
Local Institution - 0303, Merida, Yucatán
Local Institution - 0192, Chihuahua, Not set
Local Institution - 0195, San Luis Potosi, Not set
Local Institution - 0236, San Luis Potosi, Not set
Local Institution - 0194, Toluca, Not set
Local Institution - 0036, Amsterdam, Not set
Local Institution - 0189, Amsterdam, Not set
Local Institution - 0169, Breda, Not set
Local Institution - 0037, Rotterdam, Not set
Local Institution - 0039, Veldhoven, Not set
Local Institution - 0262, Lima, Not set
Local Institution - 0263, Lima, Not set
Local Institution - 0350, Lima, Not set
Local Institution - 0261, Lima, Not set
Local Institution - 0351, Lima, Not set
Local Institution - 0060, Bydgoszcz, Not set
Local Institution - 0058, Gdansk, Not set
Local Institution - 0063, Gdynia, Not set
Local Institution - 0072, Gliwice, Not set
Local Institution - 0057, Lodz, Not set
Local Institution - 0059, Warszawa, Not set
Local Institution - 0070, Wroclaw, Not set
Local Institution - 0167, Craiova, Not set
Local Institution - 0250, Floresti, Not set
Local Institution - 0166, Romania, Not set
Local Institution - 0284, Sector 2, Not set
Local Institution - 0137, Chelyabinsk, Not set
Local Institution - 0142, Kazan, Not set
Local Institution - 0022, Moscow, Not set
Local Institution - 0049, Saint-Petersburg, Not set
Local Institution - 0028, St. Petersburg, Not set
Local Institution - 0027, St. Petersburg, Not set
Local Institution - 0143, Ufa, Not set
Local Institution - 0264, Pretoria, Gauteng
Local Institution - 0234, Sandton, Gauteng
Local Institution - 0233, Saxonwold, Johannesburg, Gauteng
Local Institution - 0305, Vereeniging, Not set
Local Institution - 0064, Majadahonda, Madrid
Local Institution - 0066, Barcelona, Not set
Local Institution - 0067, Barcelona, Not set
Local Institution - 0065, Madrid, Not set
Local Institution - 0069, Sevilla, Not set
Local Institution - 0068, Valencia, Not set
Local Institution - 0243, Basel, Not set
Local Institution - 0246, Chur, Not set
Local Institution - 0244, Lausanne, Not set
Local Institution - 0245, Winterthur, Not set
Local Institution - 0139, Taichung, Not set
Local Institution - 0138, Taipei, Not set
Local Institution - 0140, Taipei, Not set
Local Institution - 0310, Taipei, Not set
Local Institution - 0141, Taoyuan city, Not set
Local Institution - 0266, Middlesborough, Cleveland
Local Institution - 0098, London, Greater London
Local Institution - 0099, Southampton, Hampshire
Local Institution - 0118, Leicester, Leicestershire
Local Institution - 0265, Birmingham, Not set
Local Institution - 0051, Cambridgeshire, Not set
Local Institution - 0109, Edinburgh, Not set
Local Institution - 0097, London, Not set
Local Institution - 0050, London, Not set
Local Institution - 0119, Surrey, Not set
Conditions: Non-Small Cell Lung Cancer
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
Active Not Recruiting
The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel\* PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary peritoneal cancer.
The primary study hypotheses are that the combination of pembrolizumab plus carboplatin/paclitaxel\* followed by continued pembrolizumab and maintenance olaparib is superior to carboplatin/paclitaxel alone with respect to Progres... Read More
The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel\* PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary peritoneal cancer.
The primary study hypotheses are that the combination of pembrolizumab plus carboplatin/paclitaxel\* followed by continued pembrolizumab and maintenance olaparib is superior to carboplatin/paclitaxel alone with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in participants with programmed death-ligand 1 (PD-L1)-positive tumors (Combined Positive Score \[CPS\]≥10) and in all participants, and that the combination of pembrolizumab plus carboplatin/paclitaxel followed by continued pembrolizumab is superior to carboplatin/paclitaxel alone with respect to PFS per RECIST 1.1 in participants with PD-L1-positive tumors (CPS≥10) and in all participants. Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/15/2024
Locations: University of Alabama at Birmingham (UAB) ( Site 0036), Birmingham, Alabama +226 locations
University of Alabama at Birmingham (UAB) ( Site 0036), Birmingham, Alabama
University of Arizona Cancer Center ( Site 0074), Tucson, Arizona
Disney Family Cancer Center ( Site 0042), Burbank, California
Kaiser Permanente Oncology Clinical Trial -Oakland ( Site 0077), Oakland, California
Kaiser Permanente Oncology Clinical Trials-Roseville ( Site 0084), Roseville, California
Kaiser Permanente Oncology Clinical Trials-Sacramento ( Site 0083), Sacramento, California
Kaiser Permanente Oncology Clinical Trial - San Francisco ( Site 0078), San Francisco, California
Kaiser Permanente Oncology Clinical Trial - Santa Clara ( Site 0079), Santa Clara, California
Kaiser Permanente N. CA Regional Oncology Clinical Trials ( Site 0008), Vallejo, California
Kaiser Permanente Oncology Clinical Trial - Walnut Creek ( Site 0080), Walnut Creek, California
Smilow Cancer Center at Yale-New Haven ( Site 0057), New Haven, Connecticut
Sarasota Memorial Hospital ( Site 0023), Sarasota, Florida
Emory School of Medicine ( Site 0053), Atlanta, Georgia
Northeast Georgia Medical Center ( Site 0029), Gainesville, Georgia
Memorial Health University Medical Center ( Site 0011), Savannah, Georgia
Rush University Medical Center ( Site 0019), Chicago, Illinois
University of Chicago ( Site 0049), Chicago, Illinois
Dr. Sudarshan K. Sharma, LTD ( Site 0061), Hinsdale, Illinois
Saint Vincent Hospital and Health Center ( Site 0012), Indianapolis, Indiana
University of Iowa Hospital and Clinics ( Site 0005), Iowa City, Iowa
University of Kentucky ( Site 0045), Lexington, Kentucky
Weinberg Cancer Institute at Franklin Square ( Site 0035), Baltimore, Maryland
Saint Dominic - Jackson Memorial Hospital ( Site 0072), Jackson, Mississippi
Washington University - School of Medicine ( Site 0062), Saint Louis, Missouri
Nebraska Methodist Hospital ( Site 0063), Omaha, Nebraska
Dartmouth Hitchcock Medical Center ( Site 0024), Lebanon, New Hampshire
MD Anderson Cancer Center at Cooper ( Site 0067), Camden, New Jersey
Holy Name Medical Center ( Site 0037), Teaneck, New Jersey
Northwell Health- Monter Cancer Center ( Site 0075), Lake Success, New York
Sanford Roger Maris Cancer Center ( Site 0082), Fargo, North Dakota
Miami Valley Hospital [Dayton, OH] ( Site 0073), Centerville, Ohio
Oncology/Hematology Care Clinical Trials, LLC ( Site 8001), Cincinnati, Ohio
The Bing Cancer Center ( Site 0044), Columbus, Ohio
OSU Wexner Medical Center ( Site 0076), Hilliard, Ohio
Women and Infants Hospital [Providence, RI] ( Site 0039), Providence, Rhode Island
Sanford Gynecology Oncology ( Site 0004), Sioux Falls, South Dakota
Texas Oncology, P.A. - Bedford ( Site 8005), Bedford, Texas
Texas Oncology-Dallas Presbyterian Hospital ( Site 8004), Dallas, Texas
Parkland Hospital ( Site 0081), Dallas, Texas
UT Southwestern Medical Center ( Site 0046), Dallas, Texas
Texas Oncology, P.A. Texas Oncology-Tyler ( Site 8006), Tyler, Texas
Virginia Cancer Specialists, PC ( Site 8003), Gainesville, Virginia
MEDICAL COLLEGE OF WISCONSIN ( Site 0064), Milwaukee, Wisconsin
St George Hospital ( Site 2207), Kogarah, New South Wales
Cairns and Hinterland Hospital and Health Service ( Site 2201), Cairns, Queensland
Ballarat Health Services ( Site 2202), Ballarat, Victoria
Monash Health ( Site 2204), Clayton, Victoria
Sunshine Hospital. ( Site 2205), St Albans, Victoria
Imelda Ziekenhuis Bonheiden ( Site 0301), Bonheiden, Antwerpen
UZ Leuven Campus Gasthuisberg ( Site 0306), Leuven, Antwerpen
Cliniques Universitaires Saint-Luc ( Site 0312), Brussels, Bruxelles-Capitale, Region De
Grand Hopital de Charleroi ( Site 0302), Charleroi, Hainaut
CHU de Liege ( Site 0310), Liège, Liege
Jessa Ziekenhuis ( Site 0309), Hasselt, Limburg
Centre Hospitalier de l'Ardenne ( Site 0303), Libramont, Luxembourg
AZ Maria Middelares Gent ( Site 0300), Gent, Oost-Vlaanderen
UZ Gent ( Site 0307), Gent, Oost-Vlaanderen
Instituto do Cancer do Ceara ( Site 2707), Fortaleza, Ceara
Hospital Araujo Jorge Associacao de Combate ao Cancer de Goias ( Site 2708), Goiania, Goias
Hospital Erasto Gaertner ( Site 2716), Curitiba, Parana
Hospital de Caridade de Ijui ( Site 2712), Ijui, Rio Grande Do Sul
Hospital Bruno Born ( Site 2704), Lajeado, Rio Grande Do Sul
Hospital Nossa Senhora Da Conceicao ( Site 2703), Porto Alegre, Rio Grande Do Sul
Instituto Nacional de Cancer Hospital do Cancer II ( Site 2700), Rio de Janeiro, Not set
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 2714), Sao Paulo, Not set
Clinica de Pesquisas e Ctro de Estudos Onc. Ginecol. e Mamaria Ltda ( Site 2706), Sao Paulo, Not set
Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 2710), Sao Paulo, Not set
Tom Baker Cancer Centre ( Site 0200), Calgary, Alberta
Kingston Health Sciences Centre ( Site 0207), Kingston, Ontario
The Credit Valley Hospital ( Site 0206), Mississauga, Ontario
Princess Margaret Hospital.. ( Site 0202), Toronto, Ontario
CIUSSS du Saguenay-Lac-St-Jean ( Site 0218), Chicoutimi, Quebec
CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0219), Montreal, Quebec
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0208), Montreal, Quebec
Royal Victoria Hospital McGill University Health Centre ( Site 0211), Montreal, Quebec
Centro Investigación del Cáncer James Lind ( Site 2810), Temuco, Araucania
Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 2808), Temuco, Araucania
Fundacion Arturo Lopez Perez FALP ( Site 2800), Santiago, Region M. De Santiago
Sociedad Oncovida S.A. ( Site 2807), Santiago, Region M. De Santiago
Iram Cancer Research ( Site 2809), Santiago, Region M. De Santiago
Pontificia Universidad Catolica de Chile ( Site 2805), Santiago, Region M. De Santiago
Oncocentro ( Site 2801), Vina del Mar, Valparaiso
Centro Oncologico Antofagasta ( Site 2804), Antofagasta, Not set
Biomelab S A S ( Site 2900), Barranquilla, Atlantico
Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 2913), Valledupar, Cesar
Oncomedica S.A. ( Site 2911), Monteria, Cordoba
Instituto Nacional de Cancerologia E.S.E ( Site 2910), Bogota, Distrito Capital De Bogota
Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 2912), Bogota, Distrito Capital De Bogota
Centro Medico Imbanaco de Cali S.A ( Site 2909), Cali, Valle Del Cauca
Hemato Oncologos S.A. ( Site 2906), Cali, Valle Del Cauca
Fakultni nemocnice Brno ( Site 0404), Brno, Brno-mesto
Fakultni nemocnice Ostrava ( Site 0403), Ostrava-Poruba, Moravskoslezsky Kraj
Vseobecna fakultni nemocnice v Praze ( Site 0400), Praha, Praha, Hlavni Mesto
Nemocnice Na Bulovce ( Site 0401), Praha, Praha, Hlavni Mesto
Fakultni nemocnice Olomouc ( Site 0402), Olomouc, Not set
Hopital Prive Jean Mermoz ( Site 0607), Lyon, Auvergne
Centre Paul Strauss ( Site 0615), Strasbourg, Bas-Rhin
Hopital de la Timone ( Site 0617), Marseille, Bouches-du-Rhone
CHU de Brest -Site Hopital Morvan ( Site 0616), Brest, Bretagne
Institut de Cancerologie du Gard - CHU Caremeau ( Site 0610), Nimes, Gard
Institut de Cancerologie Lucien Neuwirth ( Site 0613), Saint-Priest-en-Jarez, Loire
Centre D Oncologie de Gentilly ( Site 0609), Nancy, Meurthe-et-Moselle
Institut Gustave Roussy ( Site 0600), Villejuif, Val-de-Marne
Hopital Tenon ( Site 0612), Paris, Not set
Marienhospital Stuttgart Vincenz von Paul Kliniken gGmbH ( Site 0707), Stuttgart, Baden-Wurttemberg
Klinikum Rechts der Isar. Technischen Universitaet Muenchen ( Site 0710), Muenchen, Bayern
Uniklinik RWTH Aachen ( Site 0718), Aachen, Nordrhein-Westfalen
Gynaekologisches Zentrum ( Site 0712), Bonn, Nordrhein-Westfalen
Klinikum Dortmund gGmbH ( Site 0717), Dortmund, Nordrhein-Westfalen
Universitaetsklinikum Duesseldorf ( Site 0704), Duesseldorf, Nordrhein-Westfalen
HELIOS Klinikum Krefeld ( Site 0715), Krefeld, Nordrhein-Westfalen
Universitaetsklinikum Muenster ( Site 0720), Muenster, Nordrhein-Westfalen
Caritas Klinikum Saarbruecken St. Theresia ( Site 0702), Saarbruecken, Saarland
Klinikum Chemnitz gGmbH ( Site 0711), Chemnitz, Sachsen
Staedtisches Krankenhaus Kiel GmbH ( Site 0709), Kiel, Schleswig-Holstein
Charite Campus Virchow-Klinikum - CVK ( Site 0700), Berlin, Not set
Pecsi Tudomanyegyetem Klinikai Kozpont ( Site 0805), Pecs, Baranya
Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz ( Site 0802), Miskolc, Borsod-Abauj-Zemplen
Orszagos Onkologiai Intezet ( Site 0800), Budapest, Not set
Uzsoki Utcai Korhaz ( Site 0803), Budapest, Not set
Debreceni Egyetem Klinikai Kozpont ( Site 0801), Debrecen, Not set
Soroka Medical Center ( Site 1006), Beer-Sheva, Not set
Hillel Yaffe Medical Center ( Site 1011), Hadera, Not set
Carmel Medical Center ( Site 1007), Haifa, Not set
Rambam Medical Center ( Site 1002), Haifa, Not set
Edith Wolfson Medical Center ( Site 1003), Holon, Not set
Shaare Zedek Medical Center ( Site 1005), Jerusalem, Not set
Rabin Medical Center ( Site 1004), Petah Tikva, Not set
Chaim Sheba Medical Center ( Site 1000), Ramat Gan, Not set
Sourasky Medical Center ( Site 1001), Tel Aviv, Not set
IRCCS Giovanni Paolo II. Ospedale Oncologico ( Site 1108), Bari, Abruzzo
Istituto Europeo di Oncologia ( Site 1100), Milano, Lombardia
A.O.U. Citta della Salute e della Scienza di Torino ( Site 1104), Torino, Piemonte
Istituto Oncologico Veneto IRCCS ( Site 1113), Padova, Veneto
Sacro Cuore di Gesu Fatebenefratelli ( Site 1112), Benevento, Not set
Ospedale Cannizzaro ( Site 1110), Catania, Not set
ASST Lecco. Ospedale A. Manzoni ( Site 1101), Lecco, Not set
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1115), Milano, Not set
A.O.U. Federico II di Napoli ( Site 1107), Napoli, Not set
Azienda Ospedaliera Policlinico Umberto I ( Site 1111), Roma, Not set
Policlinico Universitario Gemelli ( Site 1105), Roma, Not set
Presidio Ospedaliero Santa Chiara ( Site 1109), Trento, Not set
A.O. Univ. S. M. della Misericordia ( Site 1114), Udine, Not set
National Cancer Center Hospital East ( Site 2602), Kashiwa, Chiba
National Hospital Organization Shikoku Cancer Center ( Site 2601), Matsuyama, Ehime
Ehime University Hospital ( Site 2600), Toon, Ehime
Gunma Prefectural Cancer Center ( Site 2609), Ota, Gunma
Hokkaido University Hospital ( Site 2607), Sapporo, Hokkaido
Iwate Medical University Hospital ( Site 2606), Shiwa-gun, Iwate
St. Marianna University School of Medicine Hospital ( Site 2613), Kawasaki, Kanagawa
University of the Ryukyus Hospital ( Site 2616), Nakagami-gun, Okinawa
Saitama Medical University International Medical Center ( Site 2604), Hidaka, Saitama
Saitama Cancer Center ( Site 2614), Kitaadachi-gun, Saitama
National Defense Medical College Hospital ( Site 2608), Tokorozawa, Saitama
Kyorin University Hospital ( Site 2610), Mitaka, Tokyo
Kagoshima City Hospital ( Site 2612), Kagoshima, Not set
Niigata Cancer Center Hospital ( Site 2618), Niigata, Not set
Osaka International Cancer Institute ( Site 2617), Osaka, Not set
National Cancer Center Hospital ( Site 2605), Tokyo, Not set
Seoul National University Bundang Hospital ( Site 2404), Seongnam-si, Kyonggi-do
Seoul National University Hospital ( Site 2403), Seoul, Not set
Severance Hospital Yonsei University Health System ( Site 2400), Seoul, Not set
Asan Medical Center ( Site 2402), Seoul, Not set
Samsung Medical Center ( Site 2401), Seoul, Not set
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (, Warszawa, Mazowieckie
Bialostockie Centrum Onkologii ( Site 1412), Bialystok, Podlaskie
Szpitale Pomorskie Sp. z o.o. ( Site 1407), Gdynia, Pomorskie
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 1406), Gliwice, Slaskie
Swietokrzyskie Centrum Onkologii SPZOZ ( Site 1410), Kielce, Swietokrzyskie
Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu Medycznego im. K. Marcinkowskiego w Pozna, Poznan, Wielkopolskie
Arkhangelsk Clinical Oncological Dispensary ( Site 1508), Arkhangelsk, Arkhangel Skaya Oblast
Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1507), Ufa, Baskortostan, Respublika
A. Tsyb Medical Radiological Research Center ( Site 1513), Obninsk, Kaluzskaja Oblast
FSBI National Medical Oncology Research Center n.a. N.N. Blokhina ( Site 1500), Moscow, Moskva
FSCC of Special Types of Med. Care and Technologies ( Site 1503), Moscow, Moskva
Medical Rehabilitation Center ( Site 1502), Moscow, Moskva
City Clinical Oncology Center ( Site 1505), Saint Petersburg, Sankt-Peterburg
National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 1504), Saint-Petersburg, Sankt-Peterburg
Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1509), Kazan, Tatarstan, Respublika
Cancer Care Langenhoven Drive Oncology Centre ( Site 1701), Port Elizabeth, Eastern Cape
Groote Schuur Hospital ( Site 1704), Cape Town, Gauteng
Wits Clinical Research ( Site 1702), Johannesburg, Gauteng
Department of Medical Oncology ( Site 1703), Pretoria, Gauteng
Curo Oncology ( Site 1710), Pretoria, Gauteng
Wilgers Oncology Centre ( Site 1705), Pretoria, Gauteng
Little Company of Mary Hospital ( Site 1700), Pretoria, Gauteng
Sandton Oncology Medical Group PTY LTD ( Site 1712), Sandton, Gauteng
The Oncology Centre ( Site 1709), Durban, Kwazulu-Natal
Cancercare ( Site 1706), Cape Town, Western Cape
Outeniqua Cancercare Oncology Unit ( Site 1708), George, Western Cape
Cape Town Oncology Trials Pty Ltd ( Site 1707), Kraaifontein, Western Cape
Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 1603), Hospitalet de Llobregat, Barcelona
Xarxa Assistencial Universitaria Manresa ( Site 1605), Manresa, Barcelona
Hospital de Terrassa ( Site 1606), Terrassa, Barcelona
Hospital Universitario de Donostia ( Site 1602), Donostia, Gipuzkoa
Complejo Hospitalario Universitario A Coruna. CHUAC ( Site 1608), A Coruna, La Coruna
Instituto Valenciano de Oncologia ( Site 1601), Valencia, Valenciana, Comunitat
Hospital General Universitario de Valencia ( Site 1610), Valencia, Valenciana, Comunitat
Hospital Provincial San Pedro de Alcantara ( Site 1607), Caceres, Not set
Hospital Universitario Lucus Augusti ( Site 1609), Lugo, Not set
Clinica Universitaria de Navarra ( Site 1600), Madrid, Not set
Hospital Universitario Virgen del Rocio ( Site 1604), Sevilla, Not set
Changhua Christian Hospital ( Site 2507), Changhua, Not set
China Medical University Hospital ( Site 2506), Taichung, Not set
Taichung Veterans General Hospital ( Site 2510), Taichung, Not set
National Cheng Kung University Hospital ( Site 2508), Tainan, Not set
National Taiwan University Hospital ( Site 2502), Taipei, Not set
MacKay Memorial Hospital ( Site 2500), Taipei, Not set
Taipei Veterans General Hospital ( Site 2503), Taipei, Not set
Linkou Chang Gung Memorial Hospital ( Site 2501), Taoyuan, Not set
Istanbul Acibadem University Atakent Hospital ( Site 1902), Kucukcekmece, Istanbul
Etlik Zubeyde Hanim Kadin Hastaliklari Egitim ve Arastirma Hastanesi ( Site 1903), Ankara, Not set
Ankara UTF Cebeci Arastırma ve Uygulama Hastanesi ( Site 1905), Ankara, Not set
Akdeniz Universitesi Tıp Fakultesi ( Site 1901), Antalya, Not set
Uludag Universitesi Tip Fakultesi ( Site 1904), Bursa, Not set
Istanbul Universitesi Istanbul Tip Fakultesi ( Site 1900), Istanbul, Not set
Bakirkoy Sadi Konuk Egitim ve Arastirma Hastanesi ( Site 1907), Istanbul, Not set
Medipol Universite Hastanesi ( Site 1909), Istanbul, Not set
Sakarya Universitesi Tip Fakultesi Hastanesi ( Site 1906), Sakarya, Not set
MI Precarpathian Clinical Oncology Center ( Site 2181), Ivano-Frankivsk, Ivano-Frankivska Oblast
Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 2180), Kharkiv, Kharkivska Oblast
Municipal non-profit Enterprise Khmelnytskyi Regional Antitu-Gynecological Oncology department, Poli, Khmelnytskyi, Khmelnytska Oblast
Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 2170), Lviv, Lvivska Oblast
MI Odessa Regional Oncological Centre ( Site 2121), Odesa, Odeska Oblast
RMI - Sumy Regional Clinical Oncology Dispensary ( Site 2191), Sumy, Sumska Oblast
Central City Clinical Hospital ( Site 2150), Uzhgorod, Zakarpatska Oblast
Kyiv City Clinical Oncological Center ( Site 2140), Kyiv, Not set
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
Completed
GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in participants with selected, advanced or recurrent solid tumors with the aim to establish recommended dose(s) of GSK3359609 for further exploration as monotherapy and in combination with pembrolizu... Read More
GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in participants with selected, advanced or recurrent solid tumors with the aim to establish recommended dose(s) of GSK3359609 for further exploration as monotherapy and in combination with pembrolizumab or chemotherapy regimens. The study is comprised of two primary parts, each composed of two phases: Part 1: GSK3359609 monotherapy with Part 1A as dose escalation phase and Part 1B as cohort expansion phase; Part 2: GSK3359609 combination therapy with Part 2A pembrolizumab or GSK3174998 or chemotherapy or pembrolizumab plus chemotherapy or dostarlimab plus cobolimab or Bintrafusp alfa combination dose escalation phase and Part 2B expansion phase with pembrolizumab. The primary objective of the study is to determine the safety, tolerability, maximum tolerated dose or the maximum administered dose of GSK3359609 alone or in combination. Read Less
Gender:
ALL
Ages:
Between 18 years and 93 years
Trial Updated:
11/08/2024
Locations: GSK Investigational Site, Duarte, California +27 locations
GSK Investigational Site, Duarte, California
GSK Investigational Site, Los Angeles, California
GSK Investigational Site, Sarasota, Florida
GSK Investigational Site, New York, New York
GSK Investigational Site, New York, New York
GSK Investigational Site, Oklahoma City, Oklahoma
GSK Investigational Site, Philadelphia, Pennsylvania
GSK Investigational Site, Nashville, Tennessee
GSK Investigational Site, Nashville, Tennessee
GSK Investigational Site, Heidelberg, Victoria
GSK Investigational Site, Melbourne, Victoria
GSK Investigational Site, Nedlands, Western Australia
GSK Investigational Site, Toronto, Ontario
GSK Investigational Site, Shnghai, Not set
GSK Investigational Site, Bordeaux Cedex, Not set
GSK Investigational Site, Lyon cedex 08, Not set
GSK Investigational Site, Paris, Not set
GSK Investigational Site, Villejuif cedex, Not set
GSK Investigational Site, Siena, Toscana
GSK Investigational Site, Chiba, Not set
GSK Investigational Site, Osaka, Not set
GSK Investigational Site, Tokyo, Not set
GSK Investigational Site, Amsterdam, Not set
GSK Investigational Site, Barcelona, Not set
GSK Investigational Site, Barcelona, Not set
GSK Investigational Site, Madrid, Not set
GSK Investigational Site, Mága, Not set
GSK Investigational Site, Sevilla, Not set
Conditions: Neoplasms
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
Active Not Recruiting
RATIONALE: Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether chemotherapy and radiation therapy are more effective when given with or without additional chemotherapy in treating cervical cancer.
PURPOSE: This randomized phase III trial is studying chemotherapy... Read More
RATIONALE: Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether chemotherapy and radiation therapy are more effective when given with or without additional chemotherapy in treating cervical cancer.
PURPOSE: This randomized phase III trial is studying chemotherapy and pelvic radiation therapy to see how well they work when given with or without additional chemotherapy in treating patients with high-risk early-stage cervical cancer after radical hysterectomy. Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/07/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +124 locations
University of Alabama at Birmingham, Birmingham, Alabama
Providence Hospital, Mobile, Alabama
Providence Alaska Medical Center, Anchorage, Alaska
Arizona Center for Cancer Care-Peoria, Peoria, Arizona
Saint Joseph's Hospital and Medical Center, Phoenix, Arizona
Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California
Mercy San Juan Medical Center, Carmichael, California
City of Hope Medical Center, Duarte, California
Saint Joseph Hospital - Orange, Orange, California
Pomona Valley Hospital Medical Center, Pomona, California
Mercy Cancer Center, Sacramento, California
Mercy General Hospital Radiation Oncology Center, Sacramento, California
Saint Helena Hospital, Saint Helena, California
University of California At San Diego, San Diego, California
Penrose-Saint Francis Healthcare, Colorado Springs, Colorado
Hartford Hospital, Hartford, Connecticut
The Hospital of Central Connecticut, New Britain, Connecticut
University of Miami Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida
Memorial Healthcare System - Joe DiMaggio Children's Hospital, Hollywood, Florida
Jackson Memorial Hospital-Holtz Children's Hospital, Miami, Florida
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Baptist Hospital of Miami, Miami, Florida
Florida Hospital, Orlando, Florida
Grady Health System, Atlanta, Georgia
Northside Hospital, Atlanta, Georgia
Northeast Georgia Medical Center, Gainesville, Georgia
Memorial Health University Medical Center, Savannah, Georgia
Saint Joseph's-Candler Health System, Savannah, Georgia
Queen's Medical Center, Honolulu, Hawaii
University of Hawaii, Honolulu, Hawaii
Saint Alphonsus Regional Medical Center, Boise, Idaho
Northwestern University, Chicago, Illinois
Rush University Medical Center, Chicago, Illinois
OSF Saint Francis Medical Center, Peoria, Illinois
Saint Vincent Anderson Regional Hospital/Cancer Center, Anderson, Indiana
Saint Francis Hospital and Health Centers, Beech Grove, Indiana
Franciscan Saint Margaret Health-Hammond Campus, Hammond, Indiana
Franciscan Saint Francis Health-Indianapolis, Indianapolis, Indiana
Michiana Hematology Oncology PC-Mishawaka, Mishawaka, Indiana
University of Iowa Hospitals and Clinics, Iowa City, Iowa
Mercy Medical Center - North Iowa, Mason City, Iowa
University of Kansas Medical Center, Kansas City, Kansas
Kansas City Cancer Centers-Southwest, Overland Park, Kansas
Via Christi Regional Medical Center, Wichita, Kansas
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Greater Baltimore Medical Center, Baltimore, Maryland
Sinai Hospital of Baltimore, Baltimore, Maryland
Central Maryland Radiation Oncology in Howard County, Columbia, Maryland
Holy Cross Hospital, Silver Spring, Maryland
Hickman Cancer Center, Adrian, Michigan
Saint John Hospital and Medical Center, Detroit, Michigan
West Michigan Cancer Center, Kalamazoo, Michigan
Saint Joseph Mercy Port Huron, Port Huron, Michigan
Saint John Macomb-Oakland Hospital, Warren, Michigan
Abbott-Northwestern Hospital, Minneapolis, Minnesota
Mayo Clinic, Rochester, Minnesota
University of Mississippi Medical Center, Jackson, Mississippi
Kansas City Cancer Center - South, Kansas City, Missouri
Kansas City Cancer Centers - North, Kansas City, Missouri
Kansas City Cancer Center-Lee's Summit, Lee's Summit, Missouri
Phelps County Regional Medical Center, Rolla, Missouri
Saint John's Mercy Medical Center, Saint Louis, Missouri
Mercy Hospital Springfield, Springfield, Missouri
CoxHealth South Hospital, Springfield, Missouri
Nebraska Methodist Hospital, Omaha, Nebraska
The Nebraska Medical Center, Omaha, Nebraska
Elliot Hospital, Manchester, New Hampshire
Cooper Hospital University Medical Center, Camden, New Jersey
Morristown Memorial Hospital, Morristown, New Jersey
Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County, Mount Holly, New Jersey
UMDNJ - New Jersey Medical School, Newark, New Jersey
MD Anderson Cancer Center at Cooper-Voorhees, Voorhees, New Jersey
Montefiore Medical Center-Weiler Division, Bronx, New York
Montefiore Medical Center, Bronx, New York
State University of New York Downstate Medical Center, Brooklyn, New York
Memorial Sloan-Kettering Cancer Center, New York, New York
Highland Hospital, Rochester, New York
University of Rochester, Rochester, New York
Carolinas Medical Center, Charlotte, North Carolina
Summa Akron City Hospital/Cooper Cancer Center, Akron, Ohio
Akron General Medical Center, Akron, Ohio
Summa Barberton Hospital, Barberton, Ohio
University of Cincinnati, Cincinnati, Ohio
Case Western Reserve University, Cleveland, Ohio
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio
Summa Health Center at Lake Medina, Medina, Ohio
UHHS-Chagrin Highlands Medical Center, Orange Village, Ohio
Southern Ohio Medical Center, Portsmouth, Ohio
Robinson Radiation Oncology, Ravenna, Ohio
Cancer Care Center, Incorporated, Salem, Ohio
Ireland Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio
Flower Hospital, Sylvania, Ohio
University of Toledo, Toledo, Ohio
UHHS-Westlake Medical Center, Westlake, Ohio
Cancer Treatment Center, Wooster, Ohio
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Providence Portland Medical Center, Portland, Oregon
Providence Saint Vincent Medical Center, Portland, Oregon
Delaware County Memorial Hospital, Drexel Hill, Pennsylvania
Reading Hospital, West Reading, Pennsylvania
Lankenau Hospital, Wynnewood, Pennsylvania
Women and Infants Hospital, Providence, Rhode Island
Rapid City Regional Hospital, Rapid City, South Dakota
Sanford Cancer Center-Oncology Clinic, Sioux Falls, South Dakota
University of Tennessee - Knoxville, Knoxville, Tennessee
University of Texas Southwestern Medical Center, Dallas, Texas
M D Anderson Cancer Center, Houston, Texas
Methodist Hospital, Houston, Texas
Intermountain Medical Center, Murray, Utah
McKay-Dee Hospital Center, Ogden, Utah
Dixie Medical Center Regional Cancer Center, Saint George, Utah
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Seattle Cancer Care Alliance, Seattle, Washington
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington
Wheeling Hospital, Wheeling, West Virginia
Saint Vincent Hospital, Green Bay, Wisconsin
Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin
Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin
Aurora West Allis Medical Center, West Allis, Wisconsin
McGill University Department of Oncology, Montreal, Quebec
Pamela Youde Nethersole Eastern Hospital, Chai Wan, Not set
Seoul National University Bundang Hospital, Seongnam City, Kyeonggi-do
Seoul National University Hospital, Seoul, Not set
Gangnam Severance Hospital, Seoul, Not set
Korea Cancer Center Hospital, Seoul, Not set
Conditions: Cervical Cancer
9-ING-41 in Patients with Advanced Cancers
Active Not Recruiting
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2024
Locations: Mayo Clinic, Phoenix, Arizona +65 locations
Mayo Clinic, Phoenix, Arizona
Arizona Oncology Associates, Tucson, Arizona
The University of Arizona Cancer Center, Tucson, Arizona
University of California Irvine Health, Orange, California
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Christiana Care Health Services, Newark, Delaware
Sibley Memorial Hospital, Washington, District of Columbia
Florida Cancer Specialists - South, Fort Myers, Florida
Miami Cancer Institute, Miami, Florida
Florida Cancer Specialists - North, Saint Petersburg, Florida
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois
Des Moines Oncology Research Association, Des Moines, Iowa
Kansas University Cancer Center, Kansas City, Kansas
Ochsner Clinic Foundation, New Orleans, Louisiana
University of Michigan, Ann Arbor, Michigan
MetroMetro-Minnesota Community Oncology Research Consortium (MMCORC), Minneapolis, Minnesota
Mayo Clinic, Rochester, Minnesota
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada
Morristown Medical Center, Morristown, New Jersey
Capital Health Medical Center/ Hopewell, Pennington, New Jersey
MD Anderson Cancer Center at Cooper, Voorhees, New Jersey
Columbia University- Irving Medical Center, New York, New York
Stony Brook University Hospital, Stony Brook, New York
Duke University Medical Center, Durham, North Carolina
Oregon Health and Science University, Portland, Oregon
St. Luke's University Health Network, Bethlehem, Pennsylvania
Allegheny Health Network, Pittsburgh, Pennsylvania
Rhode Island Hospital, Providence, Rhode Island
Prisma Health Cancer Institute, Greenville, South Carolina
Sanford Research, Sioux Falls, South Dakota
West Cancer Center, Germantown, Tennessee
Baptist Clinical Research Institute, Memphis, Tennessee
Sarah Cannon Research Institute- Tennessee Oncology-Nashville, Nashville, Tennessee
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Texas Oncology- Charles A. Sammons Cancer Center, Dallas, Texas
UT Southwestern Medical Center, Dallas, Texas
Utah Cancer Specialists, Salt Lake City, Utah
Fred Hutchinson Cancer Research Center, Seattle, Washington
West Virginia University, Morgantown, West Virginia
UW Carbone Cancer Center, Madison, Wisconsin
UZA- Antwerpen, Edegem, Antwerp
Imelda VZW, Bonheiden, Not set
UZ Gent, Gent, Not set
UZ Leuven Gasthuisberg, Leuven, Not set
Cross Cancer Institute, Edmonton, Alberta
QE II Health Sciences Centre, Halifax, Nova Scotia
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre, Greenfield Park, Quebec
Jewish General Hospital, Montréal, Quebec
McGill University Health Centre, Montréal, Quebec
Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec
Center Hospitalier Regional Universitaire de Besancon - Site Jean Minjoz, Besançon, Bourgogne-Franche-Comte
CHRU Brest Hopital Morvan, Brest, Bretagne
Hopital Claude Huriez, Lille, Hauts de France
Institute de Cancerologie de Lorraine, Vandœuvre-lès-Nancy, Meurthe-et-Moselle
Institut Bergonie, Bordeaux, Nouvelle Aquitaine
Insitut de Cancerologie de l'Ouest, Saint-Herblain, Pays-de-la-Loire
Hopital de la Timone, Marseille, Not set
Netherlands Cancer Institute, Amsterdam, Not set
Fundacao Champalimaud, Lisbon, Not set
Hospital Da Luz, Lisbon, Not set
Centro Hospitalar Universitario Sao Joao, Porto, Not set
Vall d'Hebron Institute of Oncology, Barcelona, Not set
Institut Catala d'Oncologia, Barcelona, Not set
Hospital Clinico U San Carlos (HSC), Madrid, Not set
START Madrid-HM CIOCC Hospital Universitario, Madrid, Not set
INCLIVA University of Valencia, Valencia, Not set
Conditions: Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Active Not Recruiting
There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if there is no detectable EBV DNA in their plasma, then patients are randomized to either standard adjuvant cisplatin and fluorouracil chemo... Read More
There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if there is no detectable EBV DNA in their plasma, then patients are randomized to either standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and fluorouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in treating patients with nasopharyngeal cancer. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +214 locations
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
The Kirklin Clinic at Acton Road, Birmingham, Alabama
Banner University Medical Center - Tucson, Tucson, Arizona
Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California
Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California
Mills-Peninsula Medical Center, Burlingame, California
Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California
City of Hope Comprehensive Cancer Center, Duarte, California
Kaiser Permanente Dublin, Dublin, California
Fresno Cancer Center, Fresno, California
UC San Diego Moores Cancer Center, La Jolla, California
Memorial Medical Center, Modesto, California
Kaiser Permanente Oakland-Broadway, Oakland, California
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Palo Alto Medical Foundation Health Care, Palo Alto, California
Stanford Cancer Institute Palo Alto, Palo Alto, California
Kaiser Permanente-Rancho Cordova Cancer Center, Rancho Cordova, California
Rohnert Park Cancer Center, Rohnert Park, California
Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California
The Permanente Medical Group-Roseville Radiation Oncology, Roseville, California
Sutter Medical Center Sacramento, Sacramento, California
University of California Davis Comprehensive Cancer Center, Sacramento, California
South Sacramento Cancer Center, Sacramento, California
California Pacific Medical Center-Pacific Campus, San Francisco, California
UCSF Medical Center-Mount Zion, San Francisco, California
UCSF Medical Center-Mission Bay, San Francisco, California
Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California
City of Hope South Pasadena, South Pasadena, California
Kaiser Permanente Cancer Treatment Center, South San Francisco, California
Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California
Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California
SCL Health Cancer Centers of Colorado - Lutheran Medical Center, Golden, Colorado
North Colorado Medical Center, Greeley, Colorado
McKee Medical Center, Loveland, Colorado
Parker Adventist Hospital, Parker, Colorado
SCL Health Lutheran Medical Center, Wheat Ridge, Colorado
Yale University, New Haven, Connecticut
Helen F Graham Cancer Center, Newark, Delaware
Christiana Care Health System-Christiana Hospital, Newark, Delaware
Baptist MD Anderson Cancer Center, Jacksonville, Florida
Moffitt Cancer Center, Tampa, Florida
Emory Proton Therapy Center, Atlanta, Georgia
Emory University Hospital Midtown, Atlanta, Georgia
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Emory Saint Joseph's Hospital, Atlanta, Georgia
The Cancer Center of Hawaii-Pali Momi, 'Aiea, Hawaii
Queen's Medical Center, Honolulu, Hawaii
The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii
Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Rush - Copley Medical Center, Aurora, Illinois
Northwestern University, Chicago, Illinois
John H Stroger Jr Hospital of Cook County, Chicago, Illinois
Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois
Decatur Memorial Hospital, Decatur, Illinois
Crossroads Cancer Center, Effingham, Illinois
Memorial Medical Center, Springfield, Illinois
Carle Cancer Center, Urbana, Illinois
Memorial Hospital of South Bend, South Bend, Indiana
Iowa Methodist Medical Center, Des Moines, Iowa
University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa
Ascension Via Christi Hospitals Wichita, Wichita, Kansas
Wesley Medical Center, Wichita, Kansas
Greater Baltimore Medical Center, Baltimore, Maryland
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Tufts Medical Center, Boston, Massachusetts
Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Boston Medical Center, Boston, Massachusetts
Saint Joseph Mercy Hospital, Ann Arbor, Michigan
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
McLaren Cancer Institute-Bay City, Bay City, Michigan
Henry Ford Cancer Institute-Downriver, Brownstown, Michigan
Saint Joseph Mercy Canton, Canton, Michigan
McLaren Cancer Institute-Clarkston, Clarkston, Michigan
Henry Ford Macomb Hospital-Clinton Township, Clinton Township, Michigan
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan
Henry Ford Hospital, Detroit, Michigan
Weisberg Cancer Treatment Center, Farmington Hills, Michigan
McLaren Cancer Institute-Flint, Flint, Michigan
Singh and Arora Hematology Oncology PC, Flint, Michigan
Karmanos Cancer Institute at McLaren Greater Lansing, Lansing, Michigan
Mid-Michigan Physicians-Lansing, Lansing, Michigan
Sparrow Hospital, Lansing, Michigan
McLaren Cancer Institute-Lapeer Region, Lapeer, Michigan
Trinity Health Saint Mary Mercy Livonia Hospital, Livonia, Michigan
McLaren Cancer Institute-Macomb, Mount Clemens, Michigan
McLaren Cancer Institute-Central Michigan, Mount Pleasant, Michigan
McLaren Cancer Institute-Northern Michigan, Petoskey, Michigan
Saint Joseph Mercy Oakland, Pontiac, Michigan
McLaren-Port Huron, Port Huron, Michigan
Ascension Saint Mary's Hospital, Saginaw, Michigan
Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan
Fairview Ridges Hospital, Burnsville, Minnesota
Minnesota Oncology - Burnsville, Burnsville, Minnesota
Unity Hospital, Fridley, Minnesota
Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota
Abbott-Northwestern Hospital, Minneapolis, Minnesota
Hennepin County Medical Center, Minneapolis, Minnesota
North Memorial Medical Health Center, Robbinsdale, Minnesota
Mayo Clinic in Rochester, Rochester, Minnesota
Regions Hospital, Saint Paul, Minnesota
Rice Memorial Hospital, Willmar, Minnesota
Saint Francis Medical Center, Cape Girardeau, Missouri
Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri
Delbert Day Cancer Institute at PCRMC, Rolla, Missouri
Washington University School of Medicine, Saint Louis, Missouri
Siteman Cancer Center-South County, Saint Louis, Missouri
Mercy Hospital Saint Louis, Saint Louis, Missouri
Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri
Mercy Hospital Springfield, Springfield, Missouri
CoxHealth South Hospital, Springfield, Missouri
Saint James Community Hospital and Cancer Treatment Center, Butte, Montana
Nebraska Methodist Hospital, Omaha, Nebraska
Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada
Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada
Renown Regional Medical Center, Reno, Nevada
Saint Mary's Regional Medical Center, Reno, Nevada
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
Memorial Sloan Kettering Monmouth, Middletown, New Jersey
Memorial Sloan Kettering Bergen, Montvale, New Jersey
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Rutgers New Jersey Medical School, Newark, New Jersey
Montefiore Medical Center-Einstein Campus, Bronx, New York
Montefiore Medical Center - Moses Campus, Bronx, New York
New York-Presbyterian/Brooklyn Methodist Hospital, Brooklyn, New York
Maimonides Medical Center, Brooklyn, New York
Memorial Sloan Kettering Commack, Commack, New York
Memorial Sloan Kettering Westchester, Harrison, New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
New York Proton Center, New York, New York
Memorial Sloan Kettering Cancer Center, New York, New York
University of Rochester, Rochester, New York
Memorial Sloan Kettering Sleepy Hollow, Sleepy Hollow, New York
Memorial Sloan Kettering Nassau, Uniondale, New York
Cleveland Clinic Akron General, Akron, Ohio
Geauga Hospital, Chardon, Ohio
University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio
Case Western Reserve University, Cleveland, Ohio
Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio
Cleveland Clinic Foundation, Cleveland, Ohio
Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Mercy Cancer Center-Elyria, Elyria, Ohio
Cleveland Clinic Cancer Center Mansfield, Mansfield, Ohio
North Coast Cancer Care, Sandusky, Ohio
Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio
ProMedica Flower Hospital, Sylvania, Ohio
University of Cincinnati Cancer Center-West Chester, West Chester, Ohio
UHHS-Westlake Medical Center, Westlake, Ohio
Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma
Legacy Mount Hood Medical Center, Gresham, Oregon
Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon
Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania
Geisinger Medical Center, Danville, Pennsylvania
Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania
Lewistown Hospital, Lewistown, Pennsylvania
Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania
Reading Hospital, West Reading, Pennsylvania
Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania
Prisma Health Cancer Institute - Spartanburg, Boiling Springs, South Carolina
Prisma Health Cancer Institute - Faris, Greenville, South Carolina
Saint Francis Cancer Center, Greenville, South Carolina
Prisma Health Cancer Institute - Eastside, Greenville, South Carolina
Prisma Health Cancer Institute - Greer, Greer, South Carolina
Gibbs Cancer Center-Pelham, Greer, South Carolina
Prisma Health Cancer Institute - Seneca, Seneca, South Carolina
Spartanburg Medical Center, Spartanburg, South Carolina
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
M D Anderson Cancer Center, Houston, Texas
American Fork Hospital / Huntsman Intermountain Cancer Center, American Fork, Utah
Sandra L Maxwell Cancer Center, Cedar City, Utah
Logan Regional Hospital, Logan, Utah
Intermountain Medical Center, Murray, Utah
McKay-Dee Hospital Center, Ogden, Utah
Utah Valley Regional Medical Center, Provo, Utah
Riverton Hospital, Riverton, Utah
Saint George Regional Medical Center, Saint George, Utah
Utah Cancer Specialists-Salt Lake City, Salt Lake City, Utah
Inova Schar Cancer Institute, Fairfax, Virginia
Inova Fairfax Hospital, Falls Church, Virginia
Naval Medical Center - Portsmouth, Portsmouth, Virginia
Legacy Salmon Creek Hospital, Vancouver, Washington
Langlade Hospital and Cancer Center, Antigo, Wisconsin
HSHS Sacred Heart Hospital, Eau Claire, Wisconsin
Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin
Gundersen Lutheran Medical Center, La Crosse, Wisconsin
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Marshfield Medical Center-Marshfield, Marshfield, Wisconsin
Marshfield Medical Center, Marshfield, Wisconsin
Medical College of Wisconsin, Milwaukee, Wisconsin
Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin
Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin
Ascension Saint Michael's Hospital, Stevens Point, Wisconsin
Marshfield Medical Center-River Region at Stevens Point, Stevens Point, Wisconsin
Aspirus Regional Cancer Center, Wausau, Wisconsin
Diagnostic and Treatment Center, Weston, Wisconsin
Marshfield Medical Center - Weston, Weston, Wisconsin
Aspirus Cancer Care - Wisconsin Rapids, Wisconsin Rapids, Wisconsin
Peter MacCallum Cancer Centre, Melbourne, Victoria
Tom Baker Cancer Centre, Calgary, Alberta
Cross Cancer Institute, Edmonton, Alberta
London Regional Cancer Program, London, Ontario
University Health Network-Princess Margaret Hospital, Toronto, Ontario
McGill University Department of Oncology, Montreal, Quebec
The Research Institute of the McGill University Health Centre (MUHC), Montreal, Quebec
Jewish General Hospital, Montreal, Quebec
Chinese University of Hong Kong-Prince of Wales Hospital, Shatin, Hong Kong
Zhongshan Hospital Fudan University, Guangdong Province, Shanghai
Sun Yat-sen University Cancer Center, Guangzhou, Not set
Pamela Youde Nethersole Eastern Hospital, Chai Wan, Not set
Centro Comprensivo de Cancer de UPR, San Juan, Not set
National Cancer Centre Singapore, Singapore, Not set
National Taiwan University Hospital, Taipei, Not set
Chang Gung Hospital-Lin Kou Medical Center, Taoyuan, Not set
Conditions: Epstein-Barr Virus Infection, Stage II Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma, Stage IVA Nasopharyngeal Carcinoma, Stage IVB Nasopharyngeal Carcinoma
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
Completed
Brief Summary:
The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated elec... Read More
Brief Summary:
The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2024
Locations: Grandview Medical Center, Cancer Center, Birmingham, Alabama +198 locations
Grandview Medical Center, Cancer Center, Birmingham, Alabama
Infirmary Cancer Care, Mobile, Alabama
Banner MD Anderson Cancer Center, Gilbert, Arizona
Arizona Oncology Associates, PC- HOPE - US Oncology Research, Tucson, Arizona
University of Arizona Cancer Center, Tucson, Arizona
Pacific Cancer Medical Center, Anaheim, California
St. Joseph Heritage Healthcare - Virginia K. Crosson Cancer Center, Fullerton, California
Cedars-Sinai Medical Center, Los Angeles, California
Dignity Health - Mercy Cancer Centers, Sacramento, California
Sutter Cancer Center Sacramento, Sacramento, California
Adventist Health St. Helena - Martin-O'Neil Cancer Center (MOCC), Saint Helena, California
Ridley-Tree Cancer Center, Santa Barbara, California
Associated Neurologists of Southern Connecticut, P.C., Milford, Connecticut
Boca Raton Regional Hospital, Lynn Cancer Institute, Boca Raton, Florida
Florida Cancer Specialists & Research Institute - Colonial Office, Fort Myers, Florida
Mayo Clinic Hospital - Florida, Jacksonville, Florida
Mount Sinai Medical Center, Miami Beach, Florida
AdventHealth Neuro Oncology, Orlando, Florida
BRCR Medical Center INC, Plantation, Florida
Florida Cancer Specialists, Saint Petersburg, Florida
Florida Hospital Tampa, Tampa, Florida
Piedmont Cancer Institute, Atlanta, Georgia
Illinois Cancer Specialist - US Oncology Research, Arlington Heights, Illinois
Rush University Medical Center, Chicago, Illinois
NorthShore University HealthSystem, Evanston, Illinois
Loyola University Medical Center, Maywood, Illinois
University of Kansas Medical Cancer Center, Fairway, Kansas
Cotton O'Neil Cancer Center (Stormont-Vail Cancer Center), Topeka, Kansas
Saint Elizabeth Healthcare, Edgewood, Kentucky
Norton Cancer Institute, Norton Healthcare Pavilion, Louisville, Kentucky
Ochsner Medical Center, New Orleans, Louisiana
Central Maine Medical Center, Clinical Research Department, Lewiston, Maine
University of Maryland Comprehensive Cancer Center, Baltimore, Maryland
Maryland Oncology Hematology, P.A - US Oncology Research, Columbia, Maryland
Beth Israel Deaconess Medical Center, Boston, Massachusetts
UMass Memorial Medical Center, Worcester, Massachusetts
Karmanos Cancer Institute, Detroit, Michigan
Cancer and Hematology Centers of Western Michigan, PC, Grand Rapids, Michigan
University of Minnesota, Minneapolis, Minnesota
MidAmerica Division, Kansas City, Missouri
Nebraska Methodist Hospital, Omaha, Nebraska
OptumCare Cancer Care, Las Vegas, Nevada
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada
Renown Institute for Heart & Vascular Health, Reno, Nevada
Astera Cancer Care, East Brunswick, New Jersey
Kaleida Health, Buffalo, New York
Bassett Medical Center, Cooperstown, New York
New York Hospital Queens, Flushing, New York
NYU Langone Arena Oncology, Lake Success, New York
White Plains Hospital - Center for Cancer Care, White Plains, New York
Novant Health Oncology Specialists, Winston-Salem, North Carolina
Gabrail Cancer Research Center, Canton, Ohio
Toledo Clinic Cancer Centers, Toledo, Ohio
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Willamette Valley Cancer Institute and Research Center - US Oncology Research, Eugene, Oregon
Geisinger Medical Center, Danville, Pennsylvania
Vita Medical Associates, P.C., Fountain Hill, Pennsylvania
UT/Erlanger Oncology & Hematology, Chattanooga, Tennessee
Tennessee Cancer Specialists, Knoxville, Tennessee
Tennessee Oncology, Nashville, Tennessee
Texas Oncology - Beaumont Mamie McFaddin Ward Cancer Center - US Oncology Research, Beaumont, Texas
Texas Oncology - Bedford - US Oncology Reasearch, Bedford, Texas
Methodist Regional Cancer Center, Dallas, Texas
Texas Oncology - Baylor - US Oncology Research, Dallas, Texas
Texas Oncology - El Paso Cancer Treatment Center Gateway - US Oncology Research, El Paso, Texas
Houston Methodist Cancer Center, Houston, Texas
Baylor Scott and White Medical Center, Temple, Texas
Texas Oncology - Tyler - US Oncology Research, Tyler, Texas
Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care - US Oncology Research, Roanoke, Virginia
Vista Oncology Inc PS, Olympia, Washington
Virginia Mason Medical Center, Seattle, Washington
Seattle Cancer Care Alliance, Seattle, Washington
West Virginia University Cancer Institute, Morgantown, West Virginia
Greenslopes Private Hospital, Greenslopes, Queensland
St. John of God Murdoch Hospital, Murdoch, Western Australia
Monash Medical Centre, Clayton, Not set
Sydney Adventist Hospital, Wahroonga, Not set
Westmead Hosptial, Westmead, Not set
Klinikum Klagenfurt am Wörthersee, Klagenfurt, Wörthersee
Medical University Graz, Graz, Not set
Univ. Klinik für Innere Medizin III der PMU, Salzburg, Not set
Landes-Krankenhaus Steyr, Steyr, Not set
Faculté de Médecine Campus Erasme, Anderlecht, Not set
UZ Leuven, Leuven, Not set
Clinique Universutaire Saint Luc - Institut Roi Albert II, Woluwe-Saint-Lambert, Not set
Centro de Pesquisa Clínica e Ensino Florianópolis LTDA, Florianópolis, Not set
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda, Ijuí, Not set
Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Not set
Hospital de Clínicas de Porto Alegre, Porto Alegre, Not set
Hospital São Lucas da PUCRS, Porto Alegre, Not set
IRPCc - Instituto Ribeirãopretano de Combate ao Câncer, Ribeirão Preto, Not set
Oncoclinicas Group Botafogo, Rio De Janeiro, Not set
Instituto D'Or de Pesquisa e Ensino - Rio De Janeiro, Rio De Janeiro, Not set
Groupo Clinicas Oncologicas Integradas (COI) - Barra da Tijuca, Rio De Janeiro, Not set
Instituto D´Or de Pesquisa e Ensino - Hospital São Rafael, São Marcos, Not set
Hospital São Rafael, São Marcos, Not set
Núcleo de Pesquisa Clínica da Rede São Camilo, São Paulo, Not set
Onco Star SP Oncologia LTDA, São Paulo, Not set
Clínica OncoStar - REDE D´OR, São Paulo, Not set
London Regional Cancer Program, London Health Sciences Centre, London, Ontario
Centre Hospitalier de I'Universitaire de de Montreal (CHUM), Montréal, Quebec
Centre Hospitalier Universitaire de Sherbrooke CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec
Sun Yat-sen Memorial Hospital Sun Yat-sen University, Guangzhou, Guangdong
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei
The First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an, Shaanxi
Linyi Cancer Hospital, Linyi, Shandong
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang
Beijing Cancer Hospital, Beijing, Not set
Peking Union Medical College Hospital, Beijing, Not set
Peking University People'S Hospital, Beijing, Not set
The first hospital of Jilin University, Changchun, Not set
Guangdong provincial people's hospital, Guangzhou, Not set
Jilin Guowen Hospital, Jilin, Not set
Shanghai Changhai Hospital, Shanghai, Not set
Shanxi Provincial Cancer Hospital, Shanxi, Not set
Xingtai People's Hospital, Xingtai, Not set
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Not set
Henan Provincial Peoples Hospital, Zhengzhou, Not set
University Hospital Centre Zagreb, Zagreb, Not set
Masaryk Institute of Oncology, Brno Střed, Not set
Nemocnice Nový Jičín, Nový Jičín, Not set
University Hospital Olomouc, Olomouc, Not set
General University Hospital in Prague, Praha 2, Not set
Nemocnice Na Bulovce, Praha 8, Not set
Hopital haut-Léveque CHU Bordeaux - Service d'Hépato- Gastroentérologie et d'Oncologie digestive, Pessac, Bordeaux
Institut de Cancérologie de l'Ouest, Angers cedex, Not set
Centre Hospitalier de Bretagne Sud /Site du Scorff, Lorient, Not set
Centre Léon Bérard, Lyon, Not set
Service d'Oncologie médicale du Pr. Andre, Hôpital Saint-Antoine, Paris, Not set
Hôpital Privé des Côtes d'Armor, Plérin, Not set
Centre de Lutte Contre le Cancer (CLCC) - Centre Paul Strauss, Strasbourg, Not set
Clinique Sainte Anne - Groupe Hospitalier Saint-Vincent, Strasbourg Oncologie Libérale, Strasbourg, Not set
Klinikum Chemnitz gGmbH, Chemnitz, Not set
Medizinische Hochschule Hannover, Klinik fur Gastroenterologie, Hepatologie und Endokrinologie, Hannover, Not set
VK und K Studien GbR Landshut-Achdorf, Landshut, Not set
Bonifatius Hospital Hematology and Oncology, Lingen, Not set
Carl-von-Basedow-klinikum Saalekrei, Merseburg, Not set
Klinikum München Bogenhausen, Klinik für Gastroenterologie und Gastroenterologische Onkologie, München, Not set
Universitätsklinikum Ulm, Ulm, Not set
Queen Mary Hospital, Hong Kong, Not set
National Institute of Oncology, Budapest, Not set
Bekes County Hospital, Gyula, Not set
Bacs-Kiskun County Hospital, Kecskemét, Not set
Tolna County Hospital, Szekszárd, Not set
Jasz-Nagykun-Szolnok County Hospital, Szolnok, Not set
Rambam Health Care Campus, Oncology Institute, Haifa, Not set
Rabin Medical Center, Petah tikva, Not set
Hadassah Medical Center, Ramat Gan, Not set
Sheba Pancreatic Cancer Center - SPCC, Ramat Gan, Not set
Sourasky Medical Center, Oncology Department, Tel Aviv, Not set
A.O. SS Antonio e Biagio e Cesare Arrigo, Alessandria, Not set
Azienda Ospedaliero-Universitaria Careggi, Firenze, Not set
Università Campus Bio-Medico di Rome, Roma, Not set
Ospedale San Giovanni Calibita Fatebenefratelli Isola Tiberina, Roma, Not set
A.O.U Città della Salute e della Scienza di Torino, Torino, Not set
Dong-A University Hospital, Seogu, Busan
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do
Keimyung University, Dongsan hospital, Daegu, Not set
National Cancer Center, Gyeonggi-do, Not set
Chonnam National University Hwasun Hospital, Hwasun, Not set
Gachon University Gil Hospital, Incheon, Not set
Inha University Hospital, Incheon, Not set
CHA Bundang Medical Center, CHA University, Seongnam-si, Not set
Severance Hospital, Yonsei University Health System, Seoul, Not set
Samsung Medical Center, Seoul, Not set
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Not set
Korea University Guro Hospital, Seoul, Not set
Ajou University Hospital, Suwon, Not set
Mediadvance Clinical, Chihuahua, Chih.
Accelerium S de RL de C.V., Monterrey, NL
Centro de Estudios de Alta Especialidad de Sinaloa, ubicado, Mazatlán, Sinaloa
Centro de Investigación Médica Aguascalientes (CIMA),, Aguascalientes, Not set
Clinstile S.A. de C.V.,, Cuauhtémoc, Not set
Phylasis Clinicas Research S. de R.L. de C.V., Cuautitlán Izcalli, Not set
Hospitales Star Medica - Luna Parc, Estado De México, Not set
Universidad Autonoma de Nuevo Leon - Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Not set
Oncocenter - Puebla, Puebla, Not set
Hospital Angeles San Luis, San Luis Potosí, Not set
Centro Potosino de Investigación Médica SC,, San Luis Potosí, Not set
Centro Hemato-Oncologico Privado CHOP, Toluca de Lerdo, Not set
Phylasis Clinicas Research S.de R.L. de C.V. (PCR)-Toluca, Toluca De Lerdo, Not set
FAICIC Clinical Research, Veracruz, Not set
Oncology Clinic Clinical Hospital of Przemienienia Pańskiego UM in Poznaniu, Poznań, Not set
Centrum Medyczne MrukMed, Rzeszów, Not set
Oncology and Radiotherapy Clinic, Oncology Center - Institute, Warsaw, Not set
Oncology and Radiotherapy Clinic University Clinical Center Non-Invasive Medicine Center, Warsaw, Not set
Jan Mikulicz-Radecki University Teaching Hospital, Wrocław, Not set
Instituto Oncòlogico Dr. Rosell, Barcelona, Not set
Vall d´Hebron University Hospital, Barcelona, Not set
Hospital General Universitario de Elche, Elche, Not set
HM Hospitales - Centro Integral Oncologico Clara Campal - CIOCC, Madrid, Not set
Hospital Regional Universitario de Málaga, Málaga, Not set
Clinica Universiatria de Navarra, Pamplona, Not set
Hospital Universitario Marqués de Valdecilla, Santander, Not set
Instituto Valenciano de Oncología IVO, Valencia, Not set
Hôpital Fribourgeois/Freiburger Spital, Fribourg, Not set
KS Winterthur, Winterthur, Not set
Conditions: Pancreas Adenocarcinoma
121 - 132 of 344